Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
160.00    -4.75 (-2.88%)
Bid:
160.00
Ask:
166.00
Spread: 6.00 (3.75%)
Market Cap: £1.38b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Hutchmed News

Hutchmed regulatory submission underway as fruquintinib trial succeeds
8 Aug 2022

Hutchmed regulatory submission underway as fruquintinib trial succeeds

(Alliance News) - Hutchmed Ltd on Monday announced phase 3 of its fruquintinib FRESCO-2 study met its primary endpoint.

TRADING UPDATES: Belvoir, Ingenta revenue up; Symphony revenue down
1 Aug 2022

TRADING UPDATES: Belvoir, Ingenta revenue up; Symphony revenue down

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

IN BRIEF: Hutchmed starts phase I trial of HMPL-A83
15 Jul 2022

IN BRIEF: Hutchmed starts phase I trial of HMPL-A83

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins phase I trial of HMPL-A83 for patients with advanced malignant neoplasms, in C...

IN BRIEF: Hutchmed presents solid results from lung cancer study
13 Jul 2022

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZene...

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up
6 Jul 2022

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Hutchmed phase I trial for IMG-007 doses first patient
6 Jul 2022

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan
1 Jun 2022

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administ...